Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Licensed for use in men and women to treat the symptoms of urge incontinence and/or increased urinary frequency
Subscribe to our email newsletter
Speciality European Pharma (SEP) has launched Regurin XL (trospium chloride), a once-daily, prolonged-release capsule to treat patients with overactive bladder (OAB) in the UK.
Regurin XL is licensed for use in men and women to treat the symptoms of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with OAB.
The company said that Regurin XL provides significant and consistent improvements in the symptoms of OAB1 and has a reduced potential for central nervous system (CNS) side effects.
The company claims that a significantly higher number of patients in placebo controlled clinical trials achieved a reduction in urgency and wet days by week 12 with Regurin XL. Furthermore, Regurin XL has the benefit of not crossing the blood-brain barrier, or the blood eye barrier reducing the CNS side effects.
Geoff McMillan, CEO of SEP, said: “As a young company with a focus on Urology, the launch of Regurin XL is very exciting. Urinary incontinence is a very common and embarrassing problem and we believe that Regurin XL offers significant benefits for patients, their physicians and the health service as a whole.”